ROME Therapeutics Announces Preclinical Data Demonstrating Inhibition of Endogenous Reverse Transcriptase Activity Blocks Immune Response in Autoimmune Disease Models
ROME Therapeutics Secures $77 Million in Series B Financing to Advance Repeatome-derived Pipeline for Cancer and Autoimmune Diseases and Expand Repeatomics Platform
ROME Therapeutics Expands Science Leadership in Oncology, Data Science and New Target Discovery
ROME Therapeutics announces the appointment of Scott Biller, Ph.D. to its board.
ROME Therapeutics announces that it has been named by Fierce Biotech as one of 2020’s Fierce 15 biotechnology companies
ROME Therapeutics Appoints Drug Discovery Veteran Dennis Zaller, Ph.D., as Chief Scientific Officer
ROME Therapeutics Launches to Develop Novel Therapies for Cancer and Autoimmune Diseases by Harnessing the Power of the Repeatome